Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab

Indian Journal of Surgical Oncology

Volumn 7, Issue 1, 2016, Pages 11-17

  Somashekhar, S P ^a   Ashwin, K R ^b   Zaveri, Shabber S ^c   Rauthan, Amit ^c   Patil, Poonam ^c  

^a MANIPAL HOSPITAL   (India)

^b Manipal Comprehensive Cancer Centre   (India)

^c Manipal Comprehensive Cancer Centre   (India)

Author keywords

Cetuximab; Colorectal; Indian study; Liver metastases; mCRR

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MORBIDITY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN TOXICITY; SURGICAL MORTALITY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84961918861     PISSN: 09757651     EISSN: 09766952     Source Type: Journal    
DOI: 10.1007/s13193-015-0442-8     Document Type: Article

References (32)

1. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49(1):8–31
2. Williams NS, Northover JMA, Arnott SJ (1995) Colorectal tumors. In: Peckham M, Pinedo H, Veronesi U (eds) Oxford textbook of oncology. Oxford University Press, Oxford, pp 1133–1168
3. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306(6880):752–755
4. Eberwein M., et. al (1998) Resection of hepatic metastases from colorectal cancer. Acta Chirurgica Austriaca 30(4):242–246
5. Adam R., et al. (2001) Five-year survival following hepatic resection after neoadjuvanttherapy for nonresectable colorectal. Ann Surg Oncol 8(4):347–353
6. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–520, discussion 520-522
7. Nordlinger B, Van Cutsem E, Rougier P et al (2007) Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 43:2037–2045
8. Van Cutsem E, Nordlinger B, Adam R et al (2006) Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212–2221
9. Scheithauer W, Kornek GV, Raderer M, Schull B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D (2003) Randomized multicenter phase ii trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21(7):1307–1312
10. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249:420–425
11. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1061, discussion 1061-1064
12. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5):663–671
13. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417
14. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47
15. Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, Bralet MP, Bouchahda M, Machover D, Ducreux M, Castagne V, Azoulay D, Castaing D (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593–4602
16. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201–1208
17. Van Cutsem E, Nowacki M, Lang S et al (2007) Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first line treatment of patients with colorectal cancer: the Crystal study. In: Proceedings of the American Society of Clinical Oncology (ASCO ‘07), vol. 25, p 164s, Chicago, Ill, USA, June 2007, abstract 4000
18. Garufi C, Torsello A, Tumulo S, Mottolese M, Campanella C, Zeuli M, Lo Re G, Pizzi G, Ettorre GM, Sperduti I (2009) POCHER (preoperative chemotherapy for hepatic resection) study with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/ leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J Clin Oncol 27:ae15020
19. De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508–515
20. Bokemeyer C, Kohne C, Rougier P, Stroh C, Schlichting M, Van Cutsem E (2010) Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clin Oncol 28:a3506
21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
22. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939–3945
23. Taylor R, Fong Y (2007) Surgical treatment of hepatic metastases from colorectal cancer. In: Blumgart LH (ed) Surgery of the liver, biliary tract, and pancreas, 4th edn. Saunders Elsevier, Philadelphia, pp 1178–1194
24. Panis Y, Ribeiro J, Chrétien Y, Nordlinger B (1992) Dormant liver metastases: an experimental study. Br J Surg 79(3):221–223
25. Abdalla EK, Hicks ME, Vauthey JN (2001) Portal vein embolization: rationale, technique and future prospects. Br J Surg 88:165–175
26. Machi J, Uchida S, Sumida K, Limm WM, Hundahl SA, Oishi AJ, Furumoto NL, Oishi RH (2001) Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg 5:477–489
27. Pérez–Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 8(suppl 1):S7–S14
28. Pérez–Soler R, Van Cutsem E (2007) Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology 21(suppl 5):10–16
29. Sipples R (2006) Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs 22(suppl 1):28–34
30. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26(14):2311–2319
31. Xiong HQ, Rosenberg A, LoBuglio A et al (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22(13):2610–2616
32. Lacouture ME, Cotliar J, Mitchell EP (2007) Clinical management ofcEGFRI dermatologic toxicities: U.S. perspective. Oncology 21(suppl 5):17–21